Therapy: The second time as farce: Rosiglitazone and the regulators

Nature Reviews Endocrinology

Volumn 7, Issue 1, 2011, Pages 5-6

  Gale, Edwin A M ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

BODY WEIGHT; CELL SURVIVAL; COMMERCIAL PHENOMENA; DIABETES MELLITUS; DRUG APPROVAL; DRUG EFFICACY; DRUG MARKETING; EUROPE; FLUID RETENTION; FOOD AND DRUG ADMINISTRATION; FRACTURE; HEART FAILURE; HEMOGLOBIN DETERMINATION; HUMAN; META ANALYSIS (TOPIC); MONOTHERAPY; NOTE; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PATIENT SAFETY; PRIORITY JOURNAL; PROFESSIONAL SECRECY; SIDE EFFECT; UNITED STATES; WEIGHT GAIN;

CHROMANS; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; THIAZOLIDINEDIONES;

EID: 78650308937     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2010.209     Document Type: Note

References (10)

1. Gale, E. A. Troglitazone: the lesson that nobody learned? Diabetologia 49, 1-6 (2006).
2. Gale, E. A. Lessons from the glitazones: a story of drug development. Lancet 357, 1870-1875 (2001).
3. Dormandy, J. A. et al. secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial in macrovascular events): a randomised controlled trial. Lancet 366, 1279-1289 (2005).
4. Kahn, W. E. et al. Glycemic durability of rosiglitazone, metformin or glyburide monotherapy. N. Engl. J. Med. 355, 2427-2443 (2006).
5. Nissen, W. E. & Wolski, K. effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457-2471 (2007).
6. Nissen, S. E. & Wolski, K. Rosiglitazone revisited. An updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch. Intern. Med. 170, 1191-1201 (2010).
7. Home, P D. et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (ReCORD): a multicentre, randomised, open-label trial. Lancet 373, 2125-2135 (2009).
8. Nissen, S. E. The rise and fall of rosiglitazone. Eur. Heart J. 31, 773-776 (2010)
9. Woodcock, J., Scharfstein, J. M. & Hamburg, M. Regulatory action on rosiglitazone by the Us Food and Drug Administration. N. Engl. J. Med. 363, 1489-1491 (2010).
10. Blind, E., Dunder, K., de Graeff, P & Abadie, E., Rosiglitazone\a european Regulatory Perspective. Diabetologia (in press).